Inhibikase Therapeutics (IKT) PE Ratio: History & Chart

Inhibikase Therapeutics, Inc.(IKT)

Biotechnology · Wilmington, DE

$2.02+0.02 (+0.75%)

Delayed quote: Oct 6, 2026, 12:40 PM EDT

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Wilmington, DE

35 employees

www.inhibikase.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mark T. Iwicki

View full financials

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Inhibikase Therapeutics, Inc. (IKT)	$266.05M	N/A	N/A	N/A	N/A
OraSure Technologies, Inc. (OSUR)vs ›	$266.10M	N/A	16.07	13.93	35.67
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$266.17M	N/A	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$267.03M	N/A	15.73	15.73	15.86
Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›	$261.87M	N/A	N/A	N/A	N/A
Scribe Therapeutics Inc. (SCTX)vs ›	$270.48M	N/A	N/A	N/A	N/A
Palisade Bio, Inc. (PALI)vs ›	$261.24M	N/A	4.44	4.44	4.44
AC Immune S.A. (ACIU)vs ›	$260.03M	N/A	14.47	14.47	17.60
Rocket Pharmaceuticals, Inc. (RCKT)vs ›	$273.53M	N/A	N/A	N/A	N/A
Anika Therapeutics, Inc. (ANIK)vs ›	$257.68M	N/A	83.73	30.92	28.56

NAME

MARKET CAP

PE RATIO

TTM

Inhibikase Therapeutics, Inc. (IKT)

$266.05M

N/A

OraSure Technologies, Inc. (OSUR)vs ›

$266.10M

N/A

16.07

13.93

35.67

Eupraxia Pharmaceuticals Inc. (EPRX)vs ›

$266.17M

N/A

EyePoint Pharmaceuticals, Inc. (EYPT)vs ›

$267.03M

N/A

15.73

15.86

Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›

$261.87M

N/A

Scribe Therapeutics Inc. (SCTX)vs ›

$270.48M

N/A

Palisade Bio, Inc. (PALI)vs ›

$261.24M

N/A

4.44

AC Immune S.A. (ACIU)vs ›

$260.03M

N/A

14.47

17.60

Rocket Pharmaceuticals, Inc. (RCKT)vs ›

$273.53M

N/A

Anika Therapeutics, Inc. (ANIK)vs ›

$257.68M

N/A

83.73

30.92

28.56

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

IKT PE Ratio Metrics

IKT Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics